Evidence map›Paper›PMID 25386788›Full record

ReviewCancers2014

Epstein-barr virus in gastric carcinoma.

Jun Nishikawa, Hironori Yoshiyama, Hisashi Iizasa, Yuichi Kanehiro, Munetaka Nakamura, Junichi Nishimura, Mari Saito, Takeshi Okamoto, Kouhei Sakai, Yutaka Suehiro and 4 more

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Cancers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05714748 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors

TypeinterventionalSponsorWest China HospitalRan2023 to 2025Enrolled19ConditionsMalignant TumorsArmsEBV mRNA vaccine
NCT05738447 phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

A Phase I Study of mRNA Vaccine for Patients With HBV-positive Advanced Hepatocellular Carcinoma

TypeinterventionalSponsorWest China HospitalRan2023 to 2025Enrolled9ConditionsLiver Cancer, Hepatocellular CarcinomaArmsHBV mRNA vaccine
NCT07004244 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies

TypeinterventionalSponsorSichuan UniversityRan2025 to 2027Enrolled20ConditionsMalignant TumorsArmsKRAS-mutated mRNA vaccine, TORIPALIMAB, Pemetrexed+carboplatin
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 335 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.Combinatorial chemistry & high throughput screening · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. The role of the Epstein-Barr virus-encoded BARF1 gene expressed in human gastric epithelial cells.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jun NishikawaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. junnis@yamaguchi-u.ac.jp.
Hironori YoshiyamaDepartment of Microbiology, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo City, Shimane 693-8501, Japan. yosiyama@med.shimane-u.ac.jp.
Hisashi IizasaDepartment of Microbiology, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo City, Shimane 693-8501, Japan. iizasah@med.shimane-u.ac.jp.
Yuichi KanehiroDepartment of Microbiology, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo City, Shimane 693-8501, Japan. kanehiro@med.shimane-u.ac.jp.
Munetaka NakamuraDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. munetaka@yamaguchi-u.ac.jp.
Junichi NishimuraDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. nishimuj@yamaguchi-u.ac.jp.
Mari SaitoDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. mari-s@zj8.so-net.ne.jp.
Takeshi OkamotoDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. tokamoto@yamaguchi-u.ac.jp.
Kouhei SakaiDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. sakaik@yamaguchi-u.ac.jp.
Yutaka SuehiroDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. ysuehiro@yamaguchi-u.ac.jp.
Takahiro YamasakiDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. t.yama@yamaguchi-u.ac.jp.
Atsunori OgaDepartment of Pathology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. oga@yamaguchi-u.ac.jp.
Hideo YanaiDepartment of Clinical Research, National Hospital Organization Kanmon Medical Center, 1-1 Sotoura, Chofu, Shimonoseki, Yamaguchi 752-8510, Japan. yanaih@kanmon-mc2.hosp.go.jp.
Isao SakaidaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. sakaida@yamaguchi-u.ac.jp.
Yamaguchi University · JPShimane University · JPShimonoseki City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Epstein-Barr virus (EBV) is detected in about 10% of gastric carcinoma cases throughout the world. In EBV-associated gastric carcinoma, all tumor cells harbor the clonal EBV genome. Gastric carcinoma associated with EBV has distinct clinicopathological features, occurs predominately in men and in younger-aged individuals, and presents a generally diffuse histological type. Most cases of EBV-associated gastric carcinoma exhibit a histology rich in lymphocyte infiltration. The immunological reactiveness in the host may represent a relatively preferable prognosis in EBV-positive cases. This fact highlights the important role of EBV in the development of EBV-associated gastric carcinoma. We have clearly proved direct infection of human gastric epithelialcells by EBV. The infection was achieved by using a recombinant EBV. Promotion of growth by EBV infection was observed in the cells. Considerable data suggest that EBV may directly contribute to the development of EBV-associated GC. This tumor-promoting effect seems to involve multiple mechanisms, because EBV affects several host proteins and pathways that normally promote apoptosis and regulate cell proliferation.

Identifiers

PMID25386788
PMCPMC4276965
OpenAlexW1999596535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.